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Assessing Prognosis by Means of
Radionuclide Perfusion Imaging:
What Technique and Which
Variables Should Be Used?*
GEORGE A. BELLER, MD, FACC
Charlottesville, Virginia
The prognostic value of exercise and pharmacologic stress
myocardial perfusion imaging has been established in thou-
sands of patients evaluated in multiple clinical studies (1–5).
The major prognostic variables on stress perfusion images
predictive of future cardiac events are a large defect size
(.25% of the left ventricle), defects in more than one coro-
nary vascular supply region suggestive of multivessel coronary
artery disease (CAD), defect reversibility reflective of induc-
ible ischemia in multiple myocardial scan segments, a large
number of nonreversible defects, transient or persistent left
ventricular (LV) cavity dilation from stress to rest images,
increased lung thallium-201 (Tl-201) uptake and a rest LV
ejection fraction measured on gated single-photon emission
computed tomography (SPECT) ,40% (6–16). Data from a
multicenter registry (17) comprising 8,408 symptomatic pa-
tients showed that the number of coronary vascular territories
with ischemia (chi-square 40.1, p , 0.0001) and the number of
territories with infarction (chi-square 55, p , 0.0001) were
independent predictors of cardiac death at a mean follow-up of
2.6 years, even after adjusting for pretest risk. In that analysis,
patients with three ischemic territories had a 5.2% mortality
rate compared with 2.3% in patients with one ischemic vascu-
lar territory identified. Perhaps the most predictive nonimag-
ing variable for future cardiac events is failure to attain a
workload .6 metabolic equivalents (METS) (18). Other high
exercise electrocardiographic (ECG) stress test variables are
failure to attain $85% of maximal predicted heart rate for age,
.2.0-mm horizontal or downsloping ST segment depression in
multiple ECG leads and an inadequate blood pressure rise
during exercise (1).
Incremental prognostic value of imaging variables. Nu-
merous studies (19–24) have shown that incremental prognos-
tic information is obtained when variables from stress myocar-
dial perfusion imaging are added to information obtained
solely from clinical and ECG stress test variables. Hachamo-
vitch et al. (23) evaluated the incremental prognostic value of
technetium-99m (Tc-99m) sestamibi SPECT imaging in 2,200
consecutive patients. When a stepwise Cox proportional haz-
ards model and receiver operating characteristic curve analysis
was used, nuclear testing added incremental prognostic value
after inclusion of the most predictive clinical and exercise
variables (global chi-square 12 for clinical variables, 31 for
clinical plus exercise test variables and 169 for clinical plus
exercise plus nuclear test variables). Some studies (15) have
shown that when clinical, ECG stress test and scintigraphic
variables are known, there is little additional prognostic infor-
mation yielded by addition of coronary angiographic variables,
such as the number of vessels with significant stenoses. Fur-
thermore, recent data (23,25,26) have indicated that the extent
of inducible hypoperfusion on post-stress SPECT perfusion
images provides superior stratification of patients with stable
chest pain attributed to known or suspected CAD into low and
high risk groups than the Duke treadmill score. Hachamovitch
et al. (23) found that in their study of 2,200 patients, 834 of
1,187 with an intermediate risk treadmill score had a normal
Tc-99m sestamibi SPECT scan that was associated with a 0.4%
rate of death or infarction during follow-up. Of the remaining
patients with intermediate risk scores, the event rate was 6.4%
and 8.9%, respectively, in patients with mild or severe SPECT
defects. Approximately 50% of patients are classified in an
intermediate risk category when the Duke treadmill score
alone is used for prognostication, leaving the clinician with
perhaps greater indecision regarding management strategy
than before treadmill test referral (25).
Perhaps the most valuable contribution of exercise or
pharmacologic stress imaging is its excellent negative predic-
tive value for predicting a low event rate in patients with a
normal scan on symptom-limited exercise testing or with
vasodilator stress imaging (1,4,27–30). Patients with normal
perfusion scans have a ,1.0 cardiac death or nonfatal infarc-
tion rate per year, even if angiographic CAD has been
demonstrated (31,32).
Tl-201 reinjection and defect reversibility. The identifica-
tion of defect reversibility on stress and 4-h redistribution
imaging can be enhanced by either quantitative scan analysis or
reinjection of a second dose of Tl-201 at rest after acquisition
of the delayed redistribution images (33–39). Application of
“reinjection” Tl-201 imaging in the clinical setting has been
directed toward improving the detection of viable myocardium
in defects that appear to be persistent, suggesting myocardial
scar, on stress and redistribution imaging. Dilsizian et al. (34)
reported that 87% of myocardial regions showing reversibility
after Tl-201 reinjection showed improved regional perfusion
and function after coronary angioplasty. Bonow et al. (40)
found an 88% concordancy rate between viability assessed on
Tl-201 reinjection imaging and positron emission tomographic–
fluorine-18 fluorodeoxyglucose evidence for viability in the same
patients.
To date, scant data exist concerning the value of Tl-201
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reinjection imaging to improve the prognostic value of conven-
tional stress/redistribution perfusion imaging. The rationale
for reinjection imaging for risk stratification is that the better
the identification of defect reversibility, the greater should be
separation of low and high risk subsets of patients with chronic
CAD. This is because the number of reversible defects is
directly related as a continuous variable to an increased
incidence of subsequent cardiac events in patients treated
medically (1–3).
Tl-201 reinjection to enhance prognostic value of stress
perfusion imaging. In this issue of the Journal, Zafrir et al.
(41) sought to retrospectively evaluate the prognostic utility of
Tl-201 reinjection versus Tl-201 stress/redistribution imaging
in the prediction of future cardiac events in 366 consecutive
patients with chronic CAD who underwent either exercise or
dipyridamole stress. Surprisingly, they found that Tl-201 rein-
jection did not contribute independent prognostic information
for cardiac events when compared with stress/redistribution
imaging, even though 107 patients showed defect reversibility
only on reinjection images. There were 159 patients showing
defect reversibility on delayed redistribution images, whereas
100 had only nonreversible defects. The death or nonfatal
infarction rate was 12% in patients showing reversible defects
by reinjection only and 12.6% in patients with reversible
defects on redistribution images, values not significantly differ-
ent than the 15% event rate in patients with solely nonrevers-
ible defects. Furthermore, in contrast to previously published
observations, the number of reversible defects on either the
redistribution or the reinjection images was not predictive of
future cardiac events. There were only 0.8 reversible defects
compared with 3.8 nonreversible defects/patient in the event
group on stress/redistribution imaging. There were only 1.1
reversible defects/patient on reinjection images in the event
group, whereas 2.7 defects/patient remained nonreversible.
Thus, the majority of the overall defect size still comprised
presumed scar after reinjection. Interestingly, the number of
nonreversible defects/patient was significantly greater in the
event group than the nonevent group on both redistribution
and reinjection images. Total size of the post-stress defect
(reversible and nonreversible), presence of LV cavity dilation
and an increased lung/heart Tl-201 ratio (on exercise imaging)
were also significant predictors of events. However, with
respect to defect size, the breakpoint between high and low
risk subsets only occurred at six or more defects (using a
nine-segment model). The event rate in the 73 patients with
five defects (.50% of the left ventricle) was no different than
the event rate in the 53 patients with two defects (see Fig. 3,
Zafrir et al. [41]). Thus, overall defect size was only discrimi-
nating when $60% of the left ventricle exhibited hypoperfu-
sion on post-stress scintigrams.
Number of reversible Tl-201 defects and subsequent car-
diac events. There are several possible explanations why de-
fect reversibility and extent of reversible defects were not
significant prognostic variables in the study of Zafrir et al. (41):
First, 40 of the 48 events were cardiac death; 8 were nonfatal
infarction. Late revascularization, an “ischemic” end point
often used in prognostic studies, was not included in the
criteria for future events. Cardiac death is more likely to be
predicted by extent of myocardial scar, increased lung Tl-201
uptake and persistent LV cavity dilation, variables reflective of
extent of myocardial damage and poor LV function, than by
variables reflective of ischemia, such as defect reversibility and
inducible ST segment depression. In fact, of the 48 patients
who had an event in the study by Zafrir et al. (41), 29 had LV
cavity dilation. The findings of the present study are consistent
with those of Travin et al. (42) who reported that occurrence of
nonfatal myocardial infarction during follow-up after exercise
Tl-201 scintigraphy was most closely associated with the extent
and severity of scintigraphic ischemia, whereas cardiac death
was significantly associated with abnormal Tl-201 lung uptake
and a low exercise workload. It should be stated that in the
study by Zafrir et al. (41), the number of patients in event or
nonevent groups with a previous myocardial infarction is not
stated, but only 171 (47%) of the 366 patients had angina
before stress testing, and ,50% in the exercise group had
inducible ST segment depression. Hence, this group of patients
with CAD may have had a lower propensity for stress-related
ischemia. This supposition is supported by the fact that only
patients with some “fixed” perfusion defects on stress/
redistribution imaging were included in the retrospective anal-
ysis. In contrast, in a different group of patients with one- or
two-vessel disease entered into the Angioplasty Compared to
Medicine (ACME) study (43), 6 (10%) of 59 patients with
nonreversible defects and 26 (18%) of 146 patients with
reversible defects died during follow-up. The mortality rate
was 20% in patients with three or more reversible defects.
Thus, the ACME patient group had a greater prevalence of
subsequent cardiac deaths associated with ischemia than with
extensive areas of scar.
Some methodologic issues may have contributed to the
finding that the presence and extent of reversible defects were
not predictive of death and nonfatal infarction in the study by
Zafrir et al. (41). Planar and not SPECT imaging was used, and
visual assessment and not quantitation was utilized for analysis
of scans. Quantitative SPECT imaging is the most sensitive
technique for identifying multiple zones of hypoperfusion and
ischemia in the distribution of the three major coronary
arteries and their branches (44). Quantitation of defect sever-
ity in the study by Zafrir et al. (41) might also have yielded
information on whether the presence of mild to moderate
Abbreviations and Acronyms
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CAD 5 coronary artery disease
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nonreversible defects (.50% Tl-201 uptake vs. peak uptake)
was more predictive of future events than severe nonreversible
defects, which are more indicative of nonviability. Several
studies (45–49) have suggested that patients with extensive
areas of hibernation composed of viable myocardium have a
high cardiac event rate with medical therapy during follow-up.
Normal patients or patients with a ,5% pretest likelihood
of CAD were not included in the study of Zafrir et al. (41);
therefore the investigators interpreting the images knew that
all images were acquired in patients with CAD and may have
been unintentionally biased and overinterpreted reversibility
on redistribution and reinjection images. This overinterpreta-
tion may be why as many as 266 patients were designated as
showing “reversibility.” Also, by not including low risk patients
with a ,5% likelihood of CAD or angiographically normal
coronary arteries and normal scan results, the extent of
ischemia or reversible defect size is more difficult to relate to
subsequent events as a continuous variable. Most previous
studies showing the prognostic value of the number of revers-
ible defects included patients with normal scans and a very low
event rate. In the study by Hachamovitch et al. (23), the event
group had 3.9 reversible defects/patient versus 0.7 for the
no-event group. Another possible explanation for lack of
predictive power of defect reversibility in the study by Zafrir et
al. (41) is that many patients were receiving anti-ischemic
medications, such as beta-blockers, calcium antagonists and
nitrates, at the time of testing. These drugs can diminish defect
size on stress images and perhaps reduce the prevalence of
defect reversibility.
One possible explanation for the lack of prognostic value of
Tl-201 reinjection in the study of Zafrir et al. (41) is that
majority of nonreversible defects seen on stress/redistribution
imaging, in fact, did not show a substantial amount of revers-
ibility after reinjection. In this study, reinjection of another rest
dose of Tl-201 only reduced the average number of nonrevers-
ible defects from 3.8 to 2.7 in the event group and from 3.0 to
2.1 in the nonevent group, when the reinjection images were
compared with the redistribution images. Thus, the amount of
“new reversibility” identified by reinjection was modest. Rein-
jection may add most to the appreciation of defect reversibility
in the visual assessment of SPECT images, where background
suppression is usually used by the computer or imaging device
to “clean up” the images and produce the clear high contrast
defects that readers prefer for interpretation (50). This back-
ground suppression can obscure the visual detection of signif-
icant residual Tl-201 uptake in a defect area and can obscure
the visual appreciation of subtle redistribution. With reinjec-
tion, the additional Tl-201 activity may be sufficient to bring the
defect over the cutoff threshold of the imaging system so that
residual activity becomes visible in the images. Zafrir et al. (41)
used planar imaging with no background suppression, thus
optimizing the visual appreciation of redistribution on delayed
images. No more was gained with reinjection imaging.
Finally, in the study of Zafrir et al. (41), 109 patients
underwent coronary artery bypass graft surgery, and 68 under-
went coronary angioplasty before or during follow-up. This
high rate of revascularization in the study cohort may have
contributed to the low prevalence of reversible defects in the
event and nonevent groups and the low prevalence of subse-
quent nonfatal infarction for the overall group (2%). The
highest risk patients with left main or three-vessel CAD may
have already undergone revascularization, reducing the isch-
emic burden associated with extensive angiographic disease.
Machecourt et al. (11) and Stratmann et al. (13) found a higher
mortality rate in patients with nonreversible or mixed defects
than in those with reversible defects, which may have been due
to revascularization of patients who manifested extensive areas
of ischemia on testing or who had high risk coronary anatomy
at coronary angiography.
The findings of the study by Zafrir et al. (41) are consistent
with other recent studies that also sought to determine the
prognostic value of Tl-201 reinjection. Tisselli et al. (51) found
that the scintigraphic variable that was the strongest predictor
of hard events was the presence of more than three nonrevers-
ible defects that remained fixed after reinjection. As in the
study by Zafrir et al. (41), the presence of reversible Tl-201
defects did not predict subsequent death or infarction. In fact,
even more than two nonreversible defects showing reversibility
after reinjection did not predict hard events. The number of
reversible defects on stress/redistribution and after reinjection
was not significantly different in the event and nonevent
groups, similar to that observed in the study of Zafrir et al.
(41). Petretta et al. (52) showed that in postinfarction patients,
Tl-201 reinjection imaging provided incremental prognostic
information to clinical, exercise and Tl-201 stress/redistribution
data, but only the sum of abnormal segments that were
reversible and moderately irreversible after reinjection was
more predictive of hard events at follow-up. The extent of
reversibility as a prognostic variable alone was not improved by
reinjection Tl-201 imaging.
What can we learn from the study of Zafrir et al. (41) and
other studies assessing the prognostic value of stress perfusion
imaging?
1. Results and conclusions of prognostic studies that seek to
identify perfusion scan variables indicative of high risk can
differ greatly depending on the criteria for patient selection,
the number of patients included with a previous infarction and
LV dysfunction, whether planar or SPECT imaging is used,
whether visual or quantitative scan analysis is undertaken,
whether only “hard” events or “hard” and “soft” events are
considered as end points, whether a high incidence of coronary
revascularization is performed either soon after scintigraphy or
during follow-up and how many low risk patients without CAD
are included.
2. It is clear from virtually all published studies that the
extent of hypoperfusion (defect size, number of segmental
defects or a summed stress score) on post-stress images is a
powerful predictor of outcome. A defect size .20% to 25% of
the left ventricle identifies a higher risk group. The extent of
defect reversibility becomes a strong predictor of outcome in
patients with a high prevalence of multivessel CAD, in which
nonfatal cardiac events (e.g., revascularization, myocardial
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infarction, hospital admission for angina) are included in the
prognostic model and where early revascularization is not
undertaken as a result of scintigraphic findings. The extent of
nonreversible defects emerges as a strong predictor of cardiac
death in patients with a previous myocardial infarction and
poor LV function but little evidence for residual ischemia.
3. Increased lung Tl-201 uptake and transient or persistent
LV cavity dilation provide supplementary prognostic informa-
tion as to defect size and extent of defect reversibility.
4. Although reinjection Tl-201 imaging enhances the detec-
tion of viability in patients with chronic CAD and LV dysfunc-
tion and improves the prediction of functional improvement
after revascularization, it does not appear to provide supple-
mental prognostic information over variables derived from
stress/redistribution Tl-201 imaging for predicting subsequent
cardiac death or infarction, at least when planar imaging is
utilized. Whether consideration of the number of mild to
moderate nonreversible defects on stress/redistribution or
stress/reinjection images as a prognostic variable improves the
prognostic value of stress perfusion imaging is unknown.
However, it does improve identification of myocardial viability.
Which patients benefit most from use of stress perfusion
imaging? Controversy still exists concerning when it is cost-
effective to add the more expensive radionuclide perfusion
imaging procedures to standard exercise ECG testing in the
evaluation of patients with suspected or known CAD. Cer-
tainly, with respect to patients who present with an unstable
chest pain syndrome of new onset associated with a high
likelihood of CAD, direct referral to cardiac catheterization
may be the most cost-effective approach. Such patients often
have ischemic ECG changes when the ECG is acquired during
or soon after resolution of pain. Also, patients with known
CAD, with or without a previous infarction, and refractory
symptoms on maximal medical therapy can be directly referred
for coronary angiography if it is the judgment that medical
therapy has failed and revascularization is indicated.
Exercise ECG stress testing alone can be the first test of
choice in patients with a ,15% likelihood of CAD on the basis
of age, gender, type of chest pain presentation, number of
CAD risk factors and ECG findings at rest. If these patients
achieve .85% of the maximal predicted heart rate for age with
a normal ECG response, no further testing appears warranted.
However, if such patients demonstrate an ischemic ST segment
response that might possibly represent a false positive test
outcome, or have no inducible ST segment depression at
,85% of maximal predicted heart rate, then repeat testing
with SPECT perfusion imaging would be indicated. Ideally,
quantitative gated SPECT with a Tc-99m–labeled agent should
be utilized. If normal perfusion and normal systolic thickening
are seen on the gated SPECT study, then no further testing is
necessary. However, these patients should be evaluated with
additional diagnostic testing to determine the etiology of the
chest pain syndrome.
Patients who benefit the most from a combined ECG stress
test and a SPECT perfusion scan at the outset are those with
a 15% to 90% or intermediate pretest likelihood of CAD. Not
only are the sensitivity and specificity of CAD detection
enhanced by radionuclide imaging, but additional prognostic
information is acquired from analysis of both the treadmill
stress test results and perfusion imaging variables, as described
earlier. If Tl-201 is used as the imaging agent, as it was in the
study of Zafrir et al. (41), then quantitative scan analysis and
measurement of the lung/heart Tl-201 ratio should be per-
formed. Acquisition of a second set of “reinjection” images in
this instance appears not to be very useful because most of the
prognostic information required for risk assessment is derived
from analysis of stress and delayed redistribution studies.
Patients with normal scan results, particularly at .70% of
maximal predicted heart rate, can be assured of a good
prognosis. In contrast, high risk patients with scintigraphic
abnormalities will most likely benefit from early coronary
angiography and revascularization strategies.
I am grateful to Jerry Curtis for providing superb editorial assistance in the
preparation of this editorial.
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